Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

25 août 2025 16h06 HE | Source: Memgen

Memgen Announces First Patient Dosed in Phase 1 Combination Cohort of MEM-288 Plus Docetaxel in Advanced Non–Small Cell Lung Cancer

Memgen Announces First Patient Dosed in Phase 1 Combination Cohort of MEM-288 Plus Docetaxel in Advanced Non–Small Cell Lung Cancer
02 déc. 2019 08h00 HE | Source: Provectus Biopharmaceuticals Inc.

Provectus Announces PV-10® Abstract Accepted for Presentation at Society of Interventional Radiology (SIR) 2020 Annual Scientific Meeting

KNOXVILLE, TN, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of lysosomal-targeting cancer immunotherapy PV-10 (rose bengal...
17 avr. 2019 16h05 HE | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Acceptances of PV-10 Poster Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting

Metastatic neuroendocrine tumors; Advanced cutaneous melanomaIntratumoral administration of PV-10 to visceral and superficial disease locationsSingle-agent and combination therapy treatment settings ...
24 juil. 2018 07h00 HE | Source: Provectus Biopharmaceuticals Inc.

PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PV-10 POSTER PRESENTATION AT ESMO 2018 CONGRESS

FOR IMMEDIATE RELEASE KNOXVILLE, TN, July 24, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company’s ongoing clinical trial of PV-10 for the treatment of...
18 oct. 2017 09h38 HE | Source: Provectus Biopharmaceuticals Inc.

PROVECTUS ANNOUNCES PRELIMINARY RESULTS FROM PHASE 1B TRIAL OF INTRALESIONAL PV-10 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR THE TREATMENT OF STAGE IV MELANOMA

– Adverse events consistent with established patterns for each drug; no unexpected toxicities observed – 50% overall objective response rate; 10% complete response; highest responses observed in...